11 Dengue fever is the most widespread of the human arbovirus diseases, with approximately 12 one third of the world's population at risk of infection. Dengue viruses are members of the 13 genus Flavivirus (family Flaviviridae) and, antigenically, they separate as four closely related 14 serotypes (1-4) that share 60 to 75 % amino acid homology. This genetic diversity 15 complicates the process of antiviral drug discovery. Thus, currently no approved dengue-16 specific therapeutic treatments are available. With the aim of providing an efficient tool for 17 dengue virus drug discovery, a collection of nineteen dengue viruses, representing the 18 genotypic diversity within the four serotypes, was developed. After phylogenetic analysis of 19 the full-length genomes, we selected relevant strains from the EVAg collection at Aix-20 Marseille University and completed the virus collection, using a reverse genetic system based 21 on the infectious sub-genomic amplicons technique. Finally, we evaluated this dengue virus 22 collection against three published dengue inhibitory compounds. NITD008, which targets the 23 highly conserved active site of the viral NS5 polymerase enzyme, exhibited similar antiviral 24 potencies against each of the different dengue genotypes in the panel. Compounds targeting 25 less conserved protein subdomains, such as the capsid inhibitor ST-148, or SDM25N, a ∂ 26 opioid receptor antagonist which indirectly targets NS4B, exhibited larger differences in 27 potency against the various genotypes of dengue viruses. These results illustrate the 28 importance of a phylogenetically based dengue virus reference panel for dengue antiviral 29 research. The collection developed in this study, which includes such representative dengue 30 viruses, has been made available to the scientific community through the European Virus 31 Archive to evaluate novel DENV antiviral candidates. 32 33 Phylogenetically based establishment of a dengue virus panel, representing all available genotypes, as a tool in dengue drug discovery
Introduction 34
Dengue virus (DENV) is a major threat to human health, with approximately one third of the 35 world's population at risk of being infected. DENV is the causative agent of dengue fever, as 36 well as the more severe dengue haemorrhagic fever (DHF) 1 and dengue shock syndrome 37 (DSS) . It belongs to the genus Flavivirus (Flaviviridae family), which comprises other 38 clinically important human pathogens, such as yellow fever virus, West Nile virus and the 39 recently emerging Zika virus 2 . DENV is an arthropod borne virus transmitted through the bite 40 of infected mosquitoes from the genus Aedes (Stegomyia). Epidemiological transmission of 41 DENV is confined to urban and peri-urban cycles for which Aedes aegypti and Ae albopictus 42 mosquitoes, respectively, are the primary transmission vectors 3 . Dengue is a positive-sense 43 single stranded RNA virus with a 10.7 kb genome encoding a single polyprotein which is 44 post-translationally processed into three structural proteins, viz., capsid (C), pre-membrane 45 (prM), envelope (E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, 46 NS4B and NS5) 4 In order to select representative genotypes, we collected dengue full-length genome sequences 88 from the NCBI database and complemented this database with those of our, still unpublished, 89 "in house" and CNR strains. We performed phylogenetic reconstructions with the maximum 90 likelihood method to assign all available genome sequences to a genotype in a serotype 91
(supplementary material Fig 1, 2, 3 Various specific dengue inhibitors that target several viral proteins involved in different 109 replication steps, have been discovered. ST-148, an inhibitor targeting the capsid structural 110 protein, has been reported to inhibit all DENV serotypes in cell culture, although with varying 111 efficiency. This inhibitor also appears promising in the AG-129 mouse model when infected 112 with a strain of DENV-2 19 . NITD008, an adenosine analogue inhibitor that targets the RNA-113 dependent RNA polymerase activity, was shown to be inhibitory against all dengue serotypes 114 as well as other flaviviruses, including West Nile virus, yellow fever virus and tick-borne 115
Powassan virus 13 . SDM25N, a ∂ opioid receptor antagonist, has been reported to target the 116 NS4B protein, probably indirectly through a cellular factor. Thus far, it has only been shown 117
to be active against a DENV-2 strain 12 . Based on the different mechanisms of action of the 3 118 compounds, their respective target and its associated sequence variability across the different 119 genotypes, we hypothesize that the antiviral activity of the compounds might differ between 120 all of the genotypes of DENV. Therefore, the antiviral activity of these three compounds was 121 assessed using a single common protocol based on a viral RNA yield reduction assay 20 . The 122 assay did not depend on the cytopathogenic potential of the strain, thus allowing for the 123 inclusion of any dengue strain in the panel tested. The compounds were assayed from 10 to 124 0.004µM, with 3-fold step-dilution in triplicate. The amount of viral RNA in the supernatant 125 medium, sampled at intervals during the growth cycle, was quantified by qRT-PCR to 126 determine the 50% maximal effective concentration (EC 50 ) ( Table 1) . 127 
133
The DENV strains of the collection showed similar sensitivity towards the nucleoside 134 analogue inhibitor NITD008 with EC 50 's ranging from 0.2µM to 2.8µM, which is in 135 accordance with previously published results 21 . 136
The capsid inhibitor ST-148 inhibited all DENV-2 genotypes with EC 50 's ranging from 0.25 137 to 1.1µM. However, only one genotype for DENV-1 (DENV-1 GIII at 0.5µM), and for 138 DENV-4 (DENV-4 GIII at 0.3µM), were inhibited by this compound. Finally, no activity was 139 observed against DENV-3 genotypes, with EC 50 's > 10µM. Although Byrd and co-workers 19 140
found that the DENV-2 serotype was the most sensitive serotype to this capsid inhibitor and 141 showed some variability in the inhibition against other serotypes, they did not fully evaluate 142 the variation in susceptibility to other serotypes sufficiently comprehensively to draw 143 conclusions. 144 SDM25N showed moderate efficacy, EC 50 's ranging from 1.7 -7.7 µM against a large 145
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